LCN2 and acute kidney injury: The early recognition of AKI through biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL), proenkephalin (PENK), and kidney injury molecule-1 (KIM-1) is critical for timely intervention and improved clinical outcomes.